"The £5.5 ($8.7) million Stratified Medicine Programme, led by the charity Cancer Research UK in partnership with the National Health Service and London-based AstraZeneca and New York-based Pfizer, aims to develop a standardized national genetic screening service to help tailor oncology treatments for patients. "
"Genetic stratification allows clinicians to determine which individuals will respond to which treatment, for instance, KRAS testing in bowel cancer to see if Amgen's Vectibix (panitumumab) and Imclone's Erbitux (cetuximab) is indicated."
------ Aldrige, Nature Biotechnology 29, 854 (2011)
Indeed, Pharma firms are moving away from the conventional "one drug fits all" doctrine. It is exciting to see how personalized medicine will pan out. Especially with each individual's data currently in seemingly fragmented states: Person X can do genetic testing on 23andMe on an array, exome sequencing and cancer profiling but she/he will never find them consolidated all under her electronic health record.
Showing posts with label cancer. Show all posts
Showing posts with label cancer. Show all posts
Sunday, November 6, 2011
Tuesday, October 18, 2011
Genome-Transcriptome-Proteome Triad
The buzz has mostly been about the three entities separately. I was trying to squeeze out a proposal for my research project for a fellowship application. Was doodling on a piece of paper.
Drawing first genetic interactions: epistasis, linkage. Then RNA interactions, among themselves, where for example you can have 22-nucleotide microRNAs (miRNA) interacting with messenger RNAs (mRNA) or you can also have RNAs regulating genes (pretty good symposium review: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1088955/). Finally, proteome can be regulated by RNAs, such as tRNA, and they can also regulate the genes via transcription factors. Basically, I drew some edges and nodes on a scrap piece of paper.
The same day, I stumbled upon this article in ScienceDaily:
http://www.sciencedaily.com/releases/2011/10/111013121514.htm
Drawing first genetic interactions: epistasis, linkage. Then RNA interactions, among themselves, where for example you can have 22-nucleotide microRNAs (miRNA) interacting with messenger RNAs (mRNA) or you can also have RNAs regulating genes (pretty good symposium review: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1088955/). Finally, proteome can be regulated by RNAs, such as tRNA, and they can also regulate the genes via transcription factors. Basically, I drew some edges and nodes on a scrap piece of paper.
The same day, I stumbled upon this article in ScienceDaily:
http://www.sciencedaily.com/releases/2011/10/111013121514.htm
Four Cell papers, published back to back. I haven't read the papers but four independent studies showing the influence of non-coding RNAs and its networks in cancer, on four different ncRNAs: long coding, miRNA, mRNA and a new ceRNA (pronounced SIR-na, competing endogenous RNA)... It shows that it seems quite a big deal. But I thought it's quite obvious for the levels in the central dogma to be interconnected. Perhaps the novelty lies in the context.
I am working on ncRNAs for now too. So might actually good to take a look at the papers.
Subscribe to:
Posts (Atom)